PeptideVS
Growth Hormone
FDA Approved
Evidence: High Quality

Tesamorelin

Also known as: Egrifta, TH9507

Brand names: Egrifta, Egrifta SV

Overview
HIV-associated lipodystrophy

Tesamorelin is an FDA-approved synthetic growth hormone releasing hormone analog specifically indicated for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. Clinical trials demonstrated significant reductions in visceral adipose tissue without affecting subcutaneous fat. While approved only for HIV-related lipodystrophy, it has gained interest for targeting stubborn abdominal fat.

Mechanism of Action

Synthetic GHRH analog that reduces visceral adipose tissue by stimulating growth hormone production

Dosage Information
ParameterDetail
AdministrationSubcutaneous injection
Typical Dose2mg daily
FrequencyDaily
Side Effects
Reported adverse effects from clinical data and post-market surveillance

Common Side Effects

Injection site reactions
Arthralgia
Peripheral edema
Myalgia
Pruritus

Serious Side Effects

Increased risk of neoplasms
Glucose intolerance
Fluid retention
Hypersensitivity reactions
!Contraindications
Do not use this peptide if any of the following apply
  • Active malignancy
  • Pregnancy
  • Disruption of hypothalamic-pituitary axis
  • Hypersensitivity to tesamorelin or mannitol
Clinical Evidence

Evidence Quality

High Quality

Clinical Trial Phase

Approved (post-market)

View Key Study
Cost Comparison
Estimated monthly costs compared to similar peptides
PeptideMonthly CostFDA Status
Tesamorelin$500 - $1200/mo
FDA Approved
MK-677$50 - $100/mo
Phase 2
CJC-1295$35 - $70/mo
Not submitted
Ipamorelin$35 - $70/mo
Not submitted
GHRP-6$35 - $70/mo
Not submitted
Compare Tesamorelin
See how Tesamorelin stacks up against similar peptides
Tesamorelin vs Sermorelin

Medical Disclaimer

The information provided on this page is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy or medication. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary.